HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for ...
Figure. Patient iPSC-derived neurons. (A) Typical neuron differentiation and maturation schedule including cell numbers. Batches of neuronal progenitors can be aliquoted and cryopreserved to be used ...
Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the ...
HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...
After being largely abandoned by big pharma, biotech, and investors for well over a decade, a renewed interest, along with a surge in funding opportunities, is being seen for advanced neuroscience ...
ST. PAUL, Minn.--(BUSINESS WIRE)-- Today, CNS Therapeutics announced the FDA approval of Gablofen® (baclofen injection) for use in the management of severe spasticity, giving healthcare providers a ...
Sage Therapeutics has been working in the area of steroid-derived compounds that affect CNS receptor signaling. A pivotal trial failed to show benefit, and they had several other clinical failures as ...
LONDON--(BUSINESS WIRE)--The global central nervous system (CNS) stimulant drugs market is expected to post a CAGR of over 5% during the period 2019-2023, according to the latest market research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback